Complete abrogation of sporozoite-induced sterile immunity by blood stage parasites of homologous and heterologous malaria species by Inoue, Megumi et al.
ORAL PRESENTATION Open Access
Complete abrogation of sporozoite-induced
sterile immunity by blood stage parasites of
homologous and heterologous malaria species
Megumi Inoue
1*, Jianxia Tang
1, Osamu Kaneko
1, Katsuyuki Yui
2, Richard Culleton
1
From Parasite to Prevention: Advances in the understanding of malaria
Edinburgh, UK. 20-22 October 2010
Immunisation of mice and humans with attenuated
sporozoites has been shown to confer sterile immunity
against infection. There are ongoing efforts to develop a
vaccine based on this system. Attenuation of sporozoites
may be achieved via irradiation, genetic modification, or
through the use of drugs targeting the blood stage para-
site. Recently, it has been shown that the administration
of chloroquine, a drug that acts exclusively against the
erythrocytic stages of malaria parasites, concurrently
with live sporozoites can induce sterile immunity against
homologous challenge with Plasmodium falciparum
sporozoites in humans. However, it is not known
whether the protection achieved against P. falciparum
will also protect against other species of human malaria
parasites, which are almost always endemic in the same
region. Given the high amount of antigen diversity
within malaria parasite species, coupled with the large
evolutionary distances between the human species, it
seems unlikely that immunity to heterologous species
would be achieved. Of concern is whether the develop-
ment of an acute blood stage infection of a heterologous
species may abrogate the immunity achieved against the
vaccine target species. This phenomenon would have
serious consequences for the deployment of an attenu-
ated sporozoite vaccine in a multispecies endemic area.
Here, we describe the results of experiments aimed at
determining whether immunity achieved against one
species of malaria parasite by sporozoite immunisation
is protective against a secondary species, and whether
the development of acute blood stage infections of the
heterologous species abrogates the immunity achieved
against the vaccine target species. As such experiments
are currently impossible using human malaria parasite
species, we have used the rodent malaria parasite species
Plasmodium vinckei and Plasmodium yoelii. These two
species were selected as they offer the widest possible
evolutionary distance between rodent malaria parasites,
although they are still much more closely related than
any two of the human species. We found that although
there was some cross protection between the species fol-
lowing sporozoite immunisation in conjunction with
mefloquine treatment, the major component of this
immunity was species specific. Mice immunised with
P. yoelii sporozoites were completely protected against
the development of blood stage infection following
P. yoelii sporozoite challenge, whereas they were com-
pletely susceptible to infection with P. vinckei. Crucially,
we found that the development of a blood stage infec-
tion of either species completely removed the sterile
protection achieved via sporozoite immunisation.
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